Confidential Information A. During and for a period of ten (10) years after the expiration or early termination of this Agreement, Institution and Principal Investigator shall retain in confidence all test articles and proprietary data and/or information obtained from Sponsor or generated pursuant to the Study including, but not limited to, the Protocol, the investigator's brochure, interim results and any other information or material disclosed under confidential disclosure agreements previously entered into between the parties ("Confidential Information"). This restriction shall not apply to Confidential Information that: (i) is or becomes public knowledge (through no fault of Institution or Principal Investigator); or (ii) is lawfully made available to Institution or Principal Investigator by an independent third party owing no obligation of confidentiality to Sponsor with regard thereto (and such lawful right can be properly demonstrated by Institution or Principal Investigator); or dokumentů, které budou předány kterémukoli inspektorovi nebo auditorovi. V případě, že bude FDA nebo jiný regulatorní orgán požadovat přijetí jakéhokoli opatření za účelem řešení jakékoli obsílky, Hlavní zkoušející a Zdravotnické zařízení přijmou po konzultaci se Zadavatelem opatření nezbytné pro řešení takovéto obsílky a souhlasí, že budou spolupracovat se Zadavatelem, pokud jde o jakoukoliv takovou obsílku nebo opatření přijaté v souvislosti s ní. 8. Náklady a platby Rozpočet pro Studii je připojen jako příloha B a začleněn do této Smlouvy odkazem. Platby stanovené v těchto rozpočtových formulářích jsou stranami této Smlouvy považovány za přiměřenou odměnu za práci provedenou danou stranou. Platby ze strany Zadavatele za služby poskytnuté Zdravotnickým zařízením a Hlavním zkoušejícím na základě této Smlouvy (i) představují přiměřenou tržní hodnotu za takové služby, (ii) byly sjednány jako transakce v běžných obchodních vztazích a (iii) nebyly určeny způsobem, který zohledňuje objem nebo hodnotu jakýchkoliv doporučení nebo jakkoliv jinak generovanou obchodní spolupráci mezi stranami. Za vykonanou práci nebo vynaložené výdaje, za xxx xx Zadavatel povinen provést platbu, nebude Zdravotnické zařízení a Hlavní zkoušející požadovat z jakéhokoliv zdroje dodatečnou úxxxxx. 0.
Confidential Information A. During and for a period of ten (10) years after the expiration or early termination of this Agreement, Institution and Principal Investigator shall retain in confidence all test articles and proprietary data and/or information obtained from Sponsor or generated pursuant to the Study including, but not limited to, the Protocol, the investigator's brochure, interim results and any other information or material disclosed under confidential disclosure agreements previously entered into between the parties ("Confidential Information"). This restriction shall not apply to Confidential Information that: Státní ústav pro kontrolu léčiv, FDA nebo jakýkoli jiný regulatorní orgán uvědomí místo provádění Studie o připravované inspekci/auditu. Hlavní zkoušející xxxx xxxx Zadavateli zprávu o výsledku inspekce/auditu a to do čtyřiadvaceti (24) hodin od přijetí takové zprávy a umožní Zadavateli spolupracovat na přípravě odpovědi na jakoukoli obsílku. Tyto reakce budou připraveny do dvou (2) týdnů od takové žádosti nebo před touto lhůtou v souladu s požadavkem příslušného regulatorního orgánu. Hlavní zkoušející také poskytne Zadavateli kopie všech dokumentů, které budou předány kterémukoli inspektorovi nebo auditorovi. V případě, že bude FDA nebo jiný regulatorní orgán požadovat přijetí jakéhokoli opatření za účelem řešení jakékoli obsílky, Hlavní zkoušející a Zdravotnické zařízení přijmou po konzultaci se Zadavatelem opatření nezbytné pro řešení takovéto obsílky a souhlasí, že budou spolupracovat se Zadavatelem, pokud jde o jakoukoliv takovou obsílku nebo opatření přijaté v souvislosti s ní. 8. Náklady a platby Rozpočet pro Studii je připojen jako příloha B a začleněn do této Smlouvy odkazem. Platby stanovené v tomto rozpočtu jsou stranami této Smlouvy považovány za přiměřenou odměnu za práci provedenou danou stranou. Platby ze strany Zadavatele za služby poskytnuté Zdravotnickým zařízením a Hlavním zkoušejícím na základě této Smlouvy (i) představují přiměřenou tržní hodnotu za takové služby, (ii) byly sjednány jako transakce v běžných obchodních vztazích a (iii) nebyly určeny způsobem, který zohledňuje objem nebo hodnotu jakýchkoliv doporučení nebo jakkoliv jinak generovanou obchodní spolupráci mezi stranami. Za vykonanou práci nebo vynaložené výdaje, za xxx xx Zadavatel povinen provést platbu, nebude Zdravotnické zařízení a Hlavní zkoušející požadovat z jakéhokoliv zdroje dodatečnou xxxxxx. 0.
Confidential Information A. During and for a period of ten (10) years after the expiration or early termination of this Agreement, Institution and Principal Investigator shall retain in confidence all test articles and proprietary data and/or information obtained from Sponsor or generated pursuant to the Study including, but not limited to, the Protocol, the investigator's brochure, interim results and any other information or material disclosed under confidential disclosure agreements previously entered into between the parties ("Confidential Information"). This restriction shall not apply to Confidential Information that: (i) is or becomes public knowledge (through no fault of Institution or Principal Investigator); or (ii) is lawfully made available to Institution or Principal Investigator by an independent third party owing no obligation of confidentiality to Sponsor with regard thereto (and such lawful right can be properly demonstrated by Institution or Principal Investigator); or (iii) is already in Institution's or Principal Investigator’s possession at the time of receipt from Sponsor (and such prior possession can be properly demonstrated by Institution or Principal Investigator); or (iv) is published in accordance with the express terms of this Agreement. B. Institution may disclose Confidential Information to the extent it is required by law, regulation, rule, act or order of any governmental authority or agency. To permit Sponsor an opportunity to intervene by seeking a protective order or other similar order, in order to limit or prevent disclosures of Confidential Information, Institution or Principal Investigator shall immediately notify Sponsor, in writing, if it is requested by a court order or a governmental authority or agency to disclose Confidential Information in Institution's or Principal Investigator’s possession and thereafter Institution or Principal Investigator shall disclose only the minimum Confidential Information required to be disclosed in order to comply, whether or not a protective order or other similar order is obtained by Sponsor. C. Subject to applicable legal and regulatory requirements, Institution and Principal Investigator agree to promptly return to Sponsor, upon its request, all Confidential Information obtained from Sponsor or belonging to Sponsor pursuant to this Agreement; provided, however, that Institution's legal counsel may retain one copy of Confidential Information in a secure location for purposes of identifying Institution's o...
Confidential Information A. The Consultant acknowledges that he will acquire information about certain matters and things which are confidential to the Company ("Confidential Information"), and which information is the exclusive property of the Company including but not limited to the following: i. product design and manufacturing information and computer programs, codes, materials, prototypes, products samples, analyses, reports;
Confidential Information A. During and for a period of ten (10) years after the expiration or early termination of this Agreement, Institution and Principal Investigator shall retain in confidence all test articles and proprietary data and/or information obtained from Sponsor or generated pursuant to the Study including, but not limited to, the Protocol, the investigator's brochure, interim results and any other information or material disclosed under confidential disclosure agreements previously entered into between the parties ("Confidential Information"). This restriction shall not apply to Confidential Information that: (i) is or becomes public knowledge (through no fault of Institution or Principal Investigator); or (ii) is lawfully made available to Institution or Principal Investigator by an independent third party owing no obligation of confidentiality to Sponsor with regard thereto (and such lawful right can be properly demonstrated by Institution or Principal Investigator); or (iii) is already in Institution's or Principal Investigator’s possession at the time of receipt from Sponsor (and such prior possession can be properly demonstrated by Institution or Principal Investigator); or (iv) is published in accordance with the express terms of this Agreement. B. Institution may disclose Confidential Information to the extent it is required by law, regulation, rule, act or order of any governmental authority or agency. To permit Sponsor an opportunity to intervene by seeking a protective order or other similar order, in order to limit or rozpočtových formulářích jsou stranami této Smlouvy považovány za přiměřenou odměnu za práci provedenou danou stranou. Platby ze strany Zadavatele za služby poskytnuté Zdravotnickým zařízením a Hlavním zkoušejícím na základě této Smlouvy (i) představují přiměřenou tržní hodnotu za takové služby, (ii) byly sjednány jako transakce v běžných obchodních vztazích a (iii) nebyly určeny způsobem, který zohledňuje objem nebo hodnotu jakýchkoliv doporučení nebo jakkoliv jinak generovanou obchodní spolupráci mezi stranami. Za vykonanou práci nebo vynaložené výdaje, za xxx xx Zadavatel povinen provést platbu, nebude Zdravotnické zařízení a Hlavní zkoušející požadovat z jakéhokoliv zdroje dodatečnou xxxxxx. 0.
Confidential Information A. The Executive agrees that she shall hold in strict confidence and shall not at any time during or after her employment with the Company, directly or indirectly, (i) reveal, report, publicize, disclose, or transfer any Confidential Information (as described below) or any part thereof to any person or entity, (ii) use any of the Confidential Information or any part thereof for any purpose other than in the course of her duties on behalf of the Company, or (iii) assist any person or entity other than the Company to secure any benefit from the Confidential Information or any part thereof. All Confidential Information (regardless of the medium retained) and all abstracts, summaries or writings based upon or reflecting any Confidential Information in the Executive's possession shall be delivered by the Executive to the Company upon request therefore by the Company or automatically upon the expiration of the Term or termination of this Agreement.
Confidential Information A. Except with the express written consent of San Xxxxxxx or as otherwise herein expressly provided, the Consultant shall not, either during the Term of this Agreement or at any time thereafter, disclose or cause to be disclosed, either directly or indirectly, any of the Confidential Information in any manner, to anyone other than to the officers, directors and management of San Xxxxxxx. b) The Confidential Information shall only be disclosed to Consultants Representatives on a "need to know" basis. Consultant shall ensure that all such Persons having access to the Confidential Information comply with the provisions of this Agreement. c) The confidentiality obligations hereunder shall not apply to any of the Confidential Information that the Consultant can demonstrate is available to the public other than as a result of disclosure by the Consultant or Consultant's Representatives. d) The confidentiality obligations hereunder shall cease to apply to any Non-Acquired Prospects one year from the date that the applicable Prospect Letter was presented to San Xxxxxxx by the Consultant. Between the fifth and twelfth months (inclusive) from the date that a Prospect Letter for a Non-Aquired Prospect was presented to San Xxxxxxx, the Consultant shall be entitled to disclose Confidential Information to a third party in exercising its rights under Subsection 3.3 b). e) The Consultant shall be entitled to disclose Confidential Information to a court of competent jurisdiction or to any regulatory body having jurisdiction, provided that: (i) The Consultant shall take reasonable steps to maintain the confidentiality of the Confidential Information by the court or regulatory body; and (ii) The Consultant shall provide San Xxxxxxx with immediate written notice of any request for disclosure.
Confidential Information A. Unless otherwise agreed or required by Law, the Institution shall treat all information relating to the Study Drug and the Study as confidential (“Confidential Information”) and shall not disclose such Confidential Information to any third party or use such Confidential Information for any purpose other than the performance of the Study without the prior written consent of Sponsor. For purposes of keeping information confidential, the Institution shall use efforts at least commensurate with those employed by the Institution for the protection of its own confidential information; provided, however, such efforts shall not be less than commercially reasonable and the use of such efforts shall not constitute a defense in the event that any of the Confidential Information is not kept confidential in accordance with the terms of this Agreement. The Institution and Principal Investigator shall inform each of their employees receiving such Confidential Information of these obligations concerning use and disclosure. The confidentiality obligations of this Agreement shall also apply to any proprietary, trade secret or other confidential information which may have been disclosed to the Institution by or on behalf of Sponsor prior or subsequent to the execution of this Agreement. Institution acknowledges that in the event of a breach of this Agreement, (i) Sponsor will suffer irreparable damage that may not be fully remedied by damages, and (ii) Sponsor shall be entitled to injunctive relief against any such breach in court, and (iii) any action taken by Sponsor shall in no way be construed to limit or otherwise restrict its rights to seek other damages or relief available under this Agreement or applicable Law. Vzhledem k povinnostem zadavatele a zdravotnického zařízení uvedené v tomto odstavci (13) zadavatel poskytne následující vybavení, které bude hlavním zkoušejícím využíváno během provádění studie: HP ElitePad 1000. Vybavení použité ve studii zůstane zadavatelovým majetkem a nebude použito k žádnému jinému účelu než k provádění této studie. 14.
Confidential Information A. During and for a period of ten (10) years after the expiration or early termination of this Agreement, Institution and Principal Investigator shall retain in confidence all test articles and proprietary data and/or information obtained from Sponsor or generated pursuant to the Study including, but not limited to, the Protocol, the investigator's brochure, interim results and any other information or material disclosed under confidential disclosure agreements previously entered into between the parties ("Confidential Information"). This restriction shall not apply to Confidential Information that: (i) is or becomes public knowledge (through no fault of Institution or Principal Investigator); or (ii) is lawfully made available to Institution or Principal Investigator by an independent third party owing no obligation of confidentiality to Sponsor with regard thereto (and such lawful right can be properly demonstrated by Institution or Principal Investigator); or (iii) is already in Institution's or Principal Investigator’s possession at the time of receipt from Sponsor (and such prior possession can be properly demonstrated by Institution or Principal Investigator); or (iv) is published in accordance with the express terms of this Agreement. B. Institution may disclose Confidential Information to the extent it is required by law, regulation, rule, act or order of any governmental authority or agency. To permit Sponsor an opportunity to intervene by seeking a protective order or other similar order, in order to limit or prevent disclosures of Confidential Information, Institution or Principal Investigator shall immediately notify Sponsor, in writing, if it is requested by a court order or a governmental authority or agency to disclose Confidential Information in vyjádřilo souhlas. Smluvní strany tímto prohlašují, že z jejich strany neexistuje žádný střet zájmů finanční či nefinanční povahy, který by bránil řádné realizaci klinického hodnocení v souladu s obecně platnými právními předpisy a regulatorními požadavky (zejména na správnou klinickou praxi). 9.
Confidential Information A. During the course of performing the workscope described, SUBCONTRACTOR may be exposed to Proprietary Information of COMPANY. The Proprietary Information may include, for example, documents, data, know-how, formulae, processes, designs, customer lists, specifications, samples, reports, findings, inventions or ideas, but not limited to these forms. Regardless of the form in which the Proprietary Information was disclosed to SUBCONTRACTOR, such Information must be identified in writing as being proprietary and confidential information of the COMPANY.
